Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesScynexis Inc

Scynexis Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
3.5 USD 0.20 ( 6.06%)
Last update at 2026-11-06T21:00:00Z
VOLUME
24650
Market Cap
43.68M

Momentum Score

…

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.34
Low
3.59
High
52 Week Price Range
3.53
Low
9.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.30
Dividend Yield
-
Revenue TTM
19.22M
Revenue Per Share
2.50
Gross Profit TTM
19.22M
Debt / Equity
0.04
ROE
-18.38%
Net Debt
-19.08M
ROCE
-15.83%
Diluted EPS TTM
-0.87

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.61M -21.14M 67.18M -67.51M -35.95M
Net income -8.61M -21.29M 67.04M -62.81M -32.87M
Selling general administrative 14.39M 14.46M 33.29M 62.96M 49.92M
Gross profit 20.60M 3.75M 124.52M 4.46M 12.85M
Reconciled depreciation - 0.00M 0.61M 0.61M 0.38M
Ebit -8.44M -20.31M 70.31M -85.76M -60.83M
Ebitda -8.12M -18.58M 70.89M -85.32M -61.73M
Depreciation and amortization 0.31M 1.73M 0.58M 0.43M -0.90M
Non operating income net other - - - - 27.54M
Operating income -16.07M -37.12M 72.67M -85.76M -60.83M
Other operating expenses 36.67M 40.86M 67.47M 90.85M 73.99M
Interest expense 0.17M 2.55M 6.12M 5.20M 2.66M
Tax provision 0.00M 0.15M 0.14M -4.70M -3.09M
Interest income 2.18M 4.29M 3.28M 1.42M 0.02M
Net interest income 1.69M 1.74M -4.17M -5.37M -3.94M
Income tax expense - 0.15M 0.14M -4.70M -3.09M
Total revenue 20.60M 3.75M 140.14M 5.09M 13.16M
Total operating expenses 36.67M 40.86M 51.85M 90.22M 73.68M
Cost of revenue - 0.00M 15.62M 0.63M 0.31M
Total other income expense net 7.46M 15.98M -5.49M 18.25M 24.87M
Net income from continuing ops -8.61M -21.29M 72.20M -62.81M -32.87M
Net income applicable to common shares - - - - -32.87M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 59.03M 90.64M 128.41M 87.81M 119.84M
Intangible assets - - - 0.41M 1.06M
Other current assets 19.11M 2.62M 5.55M 0.06M 0.00M
Total liab 9.65M 35.57M 55.45M 84.58M 78.58M
Total stockholder equity 49.38M 55.08M 72.96M 3.23M 41.26M
Deferred long term liab - - - - 0.15M
Other current liab 2.79M 3.79M 7.62M 11.40M 5.70M
Common stock 0.05M 0.04M 0.04M 0.04M 0.03M
Capital stock 0.05M 0.04M 0.04M 0.04M 0.03M
Retained earnings -385.14M -376.54M -355.25M -422.29M -359.48M
Other liab - - - - 21.41M
Other assets - - - - 7.66M
Cash 21.26M 16.05M 34.43M 45.81M 104.48M
Total current liabilities 5.73M 24.10M 16.30M 17.62M 13.62M
Current deferred revenue 0.23M 1.64M 1.19M - -
Net debt -19.08M 0.22M -19.35M 2.78M -60.86M
Short term debt 0.48M 14.10M 0.34M 0.28M 0.07M
Short long term debt - 13.69M - - -
Short long term debt total 2.17M 16.27M 15.08M 48.60M 43.63M
Other stockholder equity 434.47M 431.57M 428.17M 425.49M 400.70M
Property plant equipment - - - - 0.11M
Total current assets 40.37M 72.18M 102.12M 79.06M 109.38M
Long term investments 16.25M 15.85M 23.59M - -
Net tangible assets - - - - 40.20M
Short term investments 18.77M 43.25M 40.31M 27.69M -
Net receivables - 10.26M 21.83M 2.10M 0.86M
Long term debt - - 12.16M 45.39M 28.75M
Inventory - - 0.00M 0.90M 0.46M
Accounts payable 2.23M 4.57M 7.15M 5.94M 7.85M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - - 0.03M
Retained earnings total equity - - - - -359.48M
Non currrent assets other 0.64M 0.53M 0.17M 5.75M 6.49M
Deferred long term asset charges - - - - 0.15M
Non current assets total 18.65M 18.46M 26.30M 8.75M 10.46M
Capital lease obligations 2.17M 2.58M 2.92M 3.20M 3.27M
Long term debt total - - - - 28.75M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 24.31M 6.15M -32.73M -27.39M -1.17M
Change to liabilities - - - - 7.70M
Total cashflows from investing activities 24.31M 6.15M -34.88M - -1.17M
Net borrowings -14.00M 0.00M -36.65M - 28.75M
Total cash from financing activities -14.17M -0.14M -36.72M 48.60M 67.12M
Change to operating activities - - - - 6.54M
Net income -8.61M -21.29M 67.04M -62.81M -32.87M
Change in cash 4.85M -18.00M -11.44M -58.67M 11.39M
Begin period cash flow 16.59M 34.59M 46.03M 104.70M 93.31M
End period cash flow 21.45M 16.59M 34.59M 46.03M 104.70M
Total cash from operating activities -5.28M -24.01M 60.16M -79.88M -54.56M
Issuance of capital stock 0.01M 0.00M 0.02M 47.25M 38.56M
Depreciation 0.31M 1.73M 0.58M 0.61M 0.38M
Other cashflows from investing activities - - - - -1.17M
Change to inventory - 0.00M -8.85M -0.44M -5.29M
Change to account receivables 10.26M 11.56M -19.73M -1.24M -0.86M
Sale purchase of stock - - - - 38.57M
Other cashflows from financing activities -14.17M -0.14M -0.09M 1.38M 29.82M
Change to netincome - - - - -26.72M
Capital expenditures 0.00M 0.00M 60.16M 0.01M 1.17M
Change receivables - - - - -0.86M
Cash flows other operating - - - - 1.79M
Cash and cash equivalents changes - - - - 11.39M
Change in working capital 6.08M 7.28M -30.64M 0.76M 3.15M
Stock based compensation 2.85M 3.35M 2.62M 3.69M 2.09M
Other non cash items -5.92M -15.08M 20.56M -22.13M 1.50M
Free cash flow -5.28M -24.01M 60.16M -79.89M -55.73M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SCYX
Scynexis Inc		 0.20
6.06%		 3.50 - 1.85 2.27 0.68 0.03 0.05
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Scynexis Inc

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548

201 884 5485

https://www.scynexis.com

18

Name Title Year Born
Dr. Marco Taglietti M.D. CEO, Pres & Director 1960
Mr. David Gonzalez Angulo M.D. Chief Medical Officer 1965
Mr. Ivor Macleod CPA, M.B.A. Chief Financial Officer 1962
Mr. Scott Sukenick J.D. Gen. Counsel & Corp. Sec. 1978
Debbie Etchison Exec. Director of Communications NA
Mr. David Gonzalez Angulo M.D. CEO, President & Director 1965
Mr. Scott Sukenick J.D. Chief Legal Officer & Corporate Secretary 1978
Mr. Ivor Macleod CPA, M.B.A. Chief Financial Officer 1961
Debbie Etchison Executive Director of Communications NA
Ms. Daniella Gigante Vice President of Human Resources & Information Technology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…